ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 243

Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment

Robert Katz1, Jessica Polyak Wokurka 2 and Ben Small 2, 1Rush University Medical Center, Chicago, IL, 2Rheumatology Associates, Chicago, IL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fibromyalgia, rheumatoid arthritis (RA) and Clinical Response

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Fibromyalgia & Other Clinical Pain Syndromes Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Some rheumatic disease patients have concomitant fibromyalgia.  We wanted to determine treatment response in patients with and without concomitant fibromyalgia.

Methods: Patients were diagnosed by a rheumatologist.  All patients also filled out a form to determine the presence of fibromyalgia based on the 2012 modifications of the ACR approved criteria for the diagnosis. The cut-off point was for the diagnosis of fibromyalgia was 12 or more points on a 1 to 31-point scale. Summarized counts and percentages of sex by derived DX group and for the total

  • Descriptive statistics (N, mean, SD, median, min, max, etc) for the FMS score by derived DX group and for the total 
  • Descriptive statistics  (N, mean, SD, median, min, max, etc) for the responses to “How are you responding to tx” by DX group and for the total but also summary of the counts and percentages of the number of patients having each tx score  (1, 2, 3, etc).  
  • A Kruskall-Wallis test to compare all 4 dx groups’ pain score and also the tx response score.     
  • Upon confirming that there’s indeed a difference between all 4 groups for both scores, comparisons were done, using the Mann-Whitney test and the Bonferroni correction

Results: There were 503 patients analyzed in this study; 75% were female and 25% were male. Of these, 108/503 (22%) had FMS diagnosis, 273/503 (54%) were determined to have other rheumatic diseases but no concomitant FMS (FMS score < 10), 39/503 (8%) were determined to have other rheumatic diseases and potential FMS (FMS score 10 or 11), and 83/503 (17%) were determined to have other rheumatic diseases and concomitant  FMS (FMS score > 11). See table below for a summary of these patients’ pain scores and response to treatment scores. 

The Kruskall-Wallis test for both scores and showed a significant difference between the 4 diagnosis groups for the pain score (p< 0.0001) and the response to treatment score (p< 0.0001), indicating that indeed there are differences in pain sensation and response to treatment between the 4 diagnosis groups. When multiple comparisons were performed, the ones that were statistically significantly different for the pain score were:  

Concomitant FMS vs No Concomitant  FMS (p< 0.0001) 
No Concomitant FMS vs FMS  (p< 0.0001)
No Concomitant  FMS vs Intermediate/potential Concomitant FMS  (p< 0.0001) 

This means that there are significant differences between each of those pairs of dx groups in terms of the pain score. One can conclude from this that having FMS or Concomitant FMS seems to be associated with higher pain scores.

Conclusion: Those patients who scored 12 or more points on the ACR diagnostic criteria scale were diagnosed with having fibromyalgia.  Some patients scored 10 to 12 on that scale and were considered to be intermediate in the determination of a fibromyalgia diagnosis.  Patients with inflammatory rheumatic diseases in addition to fibromyalgia (concomitant fibromyalgia) were evaluated for treatment response based on a visual analog scale. 

There was a clear difference in patients’ response to therapy in those rheumatic disease patients who had concomitant fibromyalgia and those that do not.   


Disclosure: R. Katz, None; J. Polyak Wokurka, None; B. Small, None.

To cite this abstract in AMA style:

Katz R, Polyak Wokurka J, Small B. Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/concomitant-fibromyalgia-in-patients-with-other-rheumatic-diseases-and-response-to-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/concomitant-fibromyalgia-in-patients-with-other-rheumatic-diseases-and-response-to-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology